Status:
COMPLETED
Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study
Lead Sponsor:
Eli Lilly and Company
Conditions:
Submassive Pulmonary Embolism
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
An exploratory, multicenter, randomized, placebo-controlled, double blind, dose escalation study comparing a standard therapy for submassive pulmonary embolism (Enoxaparin sodium) to a combined therap...
Eligibility Criteria
Inclusion
- Patients with symptoms of acute pulmonary embolism (PE), without an indication for fibrinolytic therapy but with echocardiographic evidence of right ventricular dysfunction (submassive PE) within 48 hours of onset of symptoms
- Clinical symptoms of Pulmonary embolism for less than 48 hours
Exclusion
- Patients with symptoms of Pulmonary embolism for more than 48 hours
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT00191724
Start Date
September 1 2004
End Date
January 1 2008
Last Update
June 24 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Mannheim, Germany